Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 35Myelodysplastic Syndromes 5Neoplasms 2Myeloproliferative Disorders 2Lymphoma, T-Cell 2Leukemia, Myelomonocytic, Chronic 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2GATA2 Deficiency 2Anemia, Refractory, with Excess of Blasts 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Neoplasm Metastasis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Hematologic Neoplasms 1Enteropathy-Associated T-Cell Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemtuzumab 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Erythroblastic, Acute × Azacitidine × 30 days × Clear all
NCT00658814 2026-05-29

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
133 enrolled 10 charts
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡